AbbVie announced a $195 million investment to expand its North Chicago manufacturing facility.

This expansion will be focusing on active pharmaceutical ingredients, as part of a broader $10 billion U.S. investment strategy.

This investment is part of AbbVie’s larger commitment to invest over $10 billion in U.S. innovation and manufacturing over the next decade. Construction of the new API facility is scheduled to begin in the fall of 2025 and is expected to be fully operational by 2027.